1. Home
  2. TKLF vs BIVI Comparison

TKLF vs BIVI Comparison

Compare TKLF & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yoshitsu Co. Ltd

TKLF

Yoshitsu Co. Ltd

HOLD

Current Price

$2.90

Market Cap

12.4M

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.33

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKLF
BIVI
Founded
2006
2013
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
8.5M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
TKLF
BIVI
Price
$2.90
$1.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.2K
107.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.62
52 Week High
$4.32
$9.09

Technical Indicators

Market Signals
Indicator
TKLF
BIVI
Relative Strength Index (RSI) 45.85 60.04
Support Level $2.19 $1.03
Resistance Level $3.40 $1.68
Average True Range (ATR) 0.20 0.10
MACD -0.01 0.02
Stochastic Oscillator 68.10 81.87

Price Performance

Historical Comparison
TKLF
BIVI

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: